Datwyler Realigns Executive Board and Sharpens Customer-Focused Innovation

Datwyler (SIX: DAE), a leading supplier of system-critical high-tech components, announces changes to its Executive Board in order to strengthen its organization and set a clear course for the future. Cindy Reiss-Clark has been appointed Chief Operating Officer (COO) of the Healthcare Division, effective 7 April 2026. She will become a member of the Executive Board. The current COO, Dirk Borghs, will step down from the Executive Board for health reasons following an extended health-related absence. The appointment of Cindy Reiss-Clark forms part of a structured and early succession plan in view of his planned retirement in 2027.

Cindy Reiss-Clark brings more than 20 years of international leadership experience in the healthcare and pharmaceutical industry. Most recently, she served as Chief Commercial Officer and member of the Executive Leadership Team at West Pharmaceutical Services, an US-listed leader in pharmaceutical packaging and delivery systems. With her strong commercial track record and deep market expertise, she will further strengthen Datwyler’s Healthcare Division as a key strategic growth pillar.

Our Healthcare division is a core driver of the long-term growth strategy. With Cindy Reiss-Clark, we are gaining an experienced and internationally proven leader who combines strategic vision with strong execution.

Dr. Paul Hälg

Chairman

In addition, Chief Technology Officer Frank Schön will step down from the Executive Board effective 1 May 2026 for personal reasons. He will take on responsibility for the R&D area “Technologies & Methods”, which brings together the company’s technological capabilities and focuses on materials, processes and engineering excellence across divisions. Following this change, the Executive Board will be more clearly aligned with the operational responsibility of the divisions and the Finance function. At the same time, innovation activities will be further sharpened and will report directly to the CEO to ensure strong strategic alignment and execution. Within this setup, “Technologies & Methods” will drive technological advancement, while “Innovation & Business Development” will focus on market-oriented development and the commercialization of new solutions. This represents a clearer alignment of existing activities rather than the creation of additional structures. As part of this, the Venture Units “Wearable Sensors” and “Soft Sensors and Actuators” will be assigned to “Innovation & Business Development” to strengthen accountability for market validation, scaling and commercialization.

These adjustments create a more transparent and sustainable structure with clear responsibilities. We are sharpening the link between our technology activities and customer value – ensuring that technological excellence is consistently translated into market-ready solutions and sustainable growth.

Volker Cwielong

CEO